NCT06427941 2026-04-17
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
BeOne Medicines
Baylor College of Medicine
Aptamer Sciences, Inc.
Memorial Sloan Kettering Cancer Center
Myeloid Therapeutics
Second Affiliated Hospital of Guangzhou Medical University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School